Anti-estrogens in the treatment of breast cancer: Current status and future directions

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 652-657

  Barker, Stewart ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Activator protein 1,; Anti estrogen; Aromatase inhibitor; Breast cancer; Selective estrogen receptor modulator

Indexed keywords

667 COUMATE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EMATE; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LETROZOLE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STERYL SULFATASE; STERYL SULFATASE INHIBITOR; TAMOXIFEN; TRIAZINE DERIVATIVE; TRILOSTANE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE MINERALIZATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; DRUG CHOICE; DRUG MECHANISM; ENDOMETRIUM CANCER; ESTROGEN RESPONSIVE ELEMENT; HUMAN; REVIEW; STRUCTURE ANALYSIS; THROMBOEMBOLISM; TREATMENT PLANNING;

ANIMALS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 0042766377     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Kaptain S, Tan LK, Chen B: HER-2/neu and breast cancer. Diagn Mol Pathol (2001) 10(3):139-152.
2. Barker S, Vinson GP: Epidermal growth factor in breast cancer. Int J Biochem (1990) 22(9):939-945. Review detailing the relationship between growth factor and estrogen receptor-driven breast cancer.
3. McDonnell DP: The molecular pharmacology of SERMs. Trends Endocrinol Metab (1999) 10(8):301-311. Review describing the origins and rationale for the SERM concept.
4. Santen RJ, Harvey HA: Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer (1999) 6(1):75-92. Comprehensive review of AI development and use, and comparisons between individuals AIs.
5. Jordan VC: Targeted anti-estrogens to prevent breast cancer. Trends Endocrinol Metab (1999) 10(8):312-317. Review discussing the benefit of tamoxifen in the clinical setting.
6. Goldstein SR: The effect of SERMs on the endometrium. Ann NY Acad Sci (2001) 949:237-242.
7. Favoni RE, De Cupis A: Steroidal and nonsteroidal oestrogen antagonists in breast cancer: Basic and clinical appraisal. Trends Pharmacol Sci (1998) 19(10):406-415. Review defining the mechanisms of tamoxifen resistance.
8. De Cassia M, Dardes R, Jordan VC: Potential benefits of SERMs on the breast. In: SERMs: A Novel Option to Maintain Health in the Menopause. Agnusdei D, Compston J (Eds), Martin Dunitz Ltd, London, UK (2000):77-89. Review of SERM use in the context of the history of tamoxifen development.
9. Dunn BK, Ford LG: From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J (2001) 7(3):144-157. Overview of the use of tamoxifen in breast cancer chemoprevention.
10. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 326(13):852-856.
11. Howell A, Howell SJ, Clarke R, Anderson E: Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol (2001) 79(1-5):227-237. Comparison and historical perspective for a wide range of hormonal therapies, including structural comparisons and a review of in vitro and clinical trial data.
12. IBIS Investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet (2002) 360(9336):817-824.
13. Vogel VG, Costantino JP, Wickerham DL, Cronin WM: National surgical adjuvant breast and bowel project update: Prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res (2003) 9(1 Pt 2):S495-S501.
14. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A et al: Double-blind, randomised trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol (2002) 20(16):3386-3395.
15. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein N, Webster A, Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol (2002) 20(16):3396-3403.
16. Martin TJ, Bryant HU: Selective oestrogen receptor modulators. In: Osteoporosis and Bone Biology: The State of the Art. Compston J, Ralston S (Eds), International Medical Press, London, UK (2000):91-106. Review of the SERM mechanism of action with a slant towards use of raloxifene in osteoporosis.
17. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 337(23):1641-1647.
18. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomised trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc (1999) 281(23):2189-2197.
19. Goldstein SR: Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer (2000) 36(Suppl 4):54-56. This paper presents a clinical trial update, which indicated that raloxifene did not stimulate endometrial proliferation in contrast to adverse effects due to tamoxifen.
20. Mosselman S, Polman J, Dijkema R: ERβ Identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 392(1):49-53.
21. Kuiper GGJM, Shughrue PJ, Merchenthaler I, Gustafsson J-Å: The estrogen receptor β subtype: A novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol (1998) 19(4):253-286.
22. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Petterson K, Warner M, Gustafsson J-Å: Mechanisms of estrogen action. Physiol Rev (2001) 81(4):1535-1565. Comprehensive review of estrogen action.
23. Lonard DM, Smith CL: Molecular perspectives on selective estrogen receptor modulators (SERMs): Progress in understanding their tissue-specific agonist and antagonist actions. Steroids (2002) 67(1):15-24.
24. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson J-Å, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 389(6652):753-758. Structural comparisons of crystals of the ER ligand-binding domain occupied by estradiol or raloxifene.
25. Pike ACW, Brzozowski AM, Hubbard RE: A structural biologist's view of the oestrogen receptor. J Steroid Biochem Mol Biol (2000) 74(5):261-268. Review of structural for ERα and ERβ in relation to co-activator interactions.
26. Parker MG: Action of 'pure' antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat (1993) 26(2):131-137.
27. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Thorsell A-G, Li Y-L, Gustafsson J-Å, Carlquist M: Structural insights into the mode of action of a pure antiestrogen. Structure (2001) (9)2:145-153.
28. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-Å, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science (1997) 277(5331):1508-1510.
29. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson J-Å, Nilsson S, Kushner PJ: The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol (1999) 13(10):1672-1685.
30. Murayama S, Fujimoto N, Asano K, Ito A: Suppression by estrogen β of AP-1 mediated transactivation through estrogen receptor α. J Steroid Biochem Mol Biol (2001) 78(2):177-184.
31. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol (2000) 74(5):311-317.
32. Chu PS, Buzdar AU, Hortobagyi GN: Trilostane and hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat (1989) 13(2):117-121.
33. Ingle JN, Krook JE, Schaid DJ, Everson LK, Mailliard JA, Long HJ, McCormack GW: Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure. Am J Clin Oncol (1990) 13(2):93-97.
34. Williams CJ, Barley VL, Blackledge GR, Rowland CG, Tyrell CJ, Bachelot F, Dermaille A, Fargeot P, Namer M, Pouillart J: Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Clin Oncol (1995) 7(2):87-92.
35. Puddefoot JR, Barker S, Glover HR, Malouitre SDM, Vinson GP: Non-competitive steroid inhibition of oestrogen receptor functions. Int J Cancer (2002) 101(1):17-22. This paper provides data suggesting a novel mechanism of action of trilostane (a drug previously used as a 3β-hydroxysteroid dehydrogenase inhibitor and now approved for use in postmenopausal breast cancer) at the ER.
36. Tyulmenkov VV, Klinge CM: Interaction of tetrahydrocrysene ketone with estrogen receptors α and β indicates conformational differences in the receptor subtypes. Arch Biochem Biophys (2000) 381(1):135-142. This paper describes 5,6,11,12-tetrahydrocrysene ketone and suggests that this fluorescent compound is able to bind to liganded and unliganded ER, and that its site of interaction in ERα and ERβ are different.
37. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL: Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol (2002) 9(5):359-364. Crystal structures of ER ligand-binding sites occupied by the selective ERβ antagonist R,R,-THC-diol, and introduction of the concept of passive antagonism.
38. Katzenellenbogen BS, Sun J, Harrington WR, Kraichely DM, Ganessunker D, Katzenellenbogen JA: Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann NY Acad Sci (2001) 949:6-15.
39. Henke BR, Consler TG, Go N, Hale RL, Hohman DR, Jones SA, Lu AT, Moore LB, Moore JT, Orban-Miller LA, Robinett RG et al: A new series of estrogen receptor modulators that display selectivity for estrogen receptor β. J Med Chem (2002) 45(25):5492-5505.
40. Norris JD, Paige LA, Christensen DJ, Chang C-Y, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP: Peptide antagonists of the human estrogen receptor. Science (1999) 285(5428):744-746. This paper describes peptide modulators of ER action which act upon motifs outside the ligand domain.
41. Hall JM, Chang C-Y, McDonnell DP: Development of peptide antagonists that target estrogen receptor β-coactivator interactions. Mol Endocrinol (2000) 14(12):2010-2023.
42. Santen RJ: To block estrogen's synthesis or action: That is the question. J Clin Endocrinol Metab (2002) 87(7):3007-3012. Comparison of SERM and AI clinical outcomes from a number of trials, supporting evidence for the use of AIs.
43. Lake DE, Hudis C: Aromatase inhibitors in breast cancer: An update. Cancer Control (2002) 9(6):490-498. Thorough exposition of AI treatment, including use in subgroups of ER-positive and HER2/neu-positive patients, demonstrating good response to letrozole compared with tamoxifen.
44. Brodie A: Aromatase inhibitors in breast cancer. Trends Endocrinol Metab (2002) 13(2):61-65. Aromatase inhibitors in clinical trials and animal tumor models.
45. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleebom HP, Janicke F, Pluzanska A et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 19(10):2596-2606.
46. Bonneterre J, Buzdar A, Nabholtz J-MA, Robertson JFR, Thurliman B, Von Eurler M, Sahmoud T, Webster A, Steinberg M: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomised trials designed for combined analysis. Cancer (2001) 92(9):2247-2258.
47. Mokbel K, Kirkpatrick KL: Recent advances in breast cancer (The 24th San Antonio Breast Cancer Symposium, December, 2001). Curr Med Res Opin (2002) 18(1):26-29.
48. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet (2002) 359(9324):2131-2139.
49. Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri EM, Nardi M, Papaldo P, Fabi A, Paoloni F, Cognetti F: Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable? Ann Oncol (2001) 12(11):1539-1543.
50. Cummings SR, Black D, Barrett-Connor E, Scott J, Wallace RB: Alendronate and fracture prevention. J Am Med Assoc (1999) 282(4):324-325.
51. Santen RJ, Leszczynski D, Tilson-Mallet N, Feil PD, Wright C, Manni A, Santner SJ: Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase versus sulfatase pathways. Ann NY Acad Sci (1986) 464:126-137. This paper presents early work which suggests that the supply of estrogen to the breast tumor may be more important than that derived by aromatase conversion of adrenal androgens in the postmenopausal woman.
52. Purohit A, Woo LWL, Potter BVL, Reed MJ: In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667-COUMATE. Cancer Res (2000) 60(13):3394-3396.
53. Purohit A, Woo LWL, Chander SK, Newman SP, Ireson C, Ho Y, Grasso A, Leese MP, Potter BVL, Reed MJ: Steroid sulphatase inhibitors for breast cancer therapy. J Steroid Biochem Mol Biol (2003) in press. This paper describes the development of a series of steroid sulfatase inhibitors including their effects on aromatase.
54. NCI's gateway for information about breast cancer. National Cancer Institute, Bethesda, MD, USA (2002). http:www.nci.nih.gov/search/clinical_trials
55. Ingle JN: Sequencing of hormonal therapy in breast cancer. Breast J (2002) 8(6):332-337.
56. Saj S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J.-Å, Toi M: Clinical impact of assay of estrogen receptor βcx in breast cancer. Breast Cancer (2002) 9(4):303-307.
57. Sgroi DC, Teng S, Robinson G, Le Vangie R, Hudson JR Jr, Elkahloun AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res (1999) 59(22):5656-5661.
58. Ross DT, Perou CM: A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers (2001) 17(2):99-109.
59. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S: Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol (2002) 29(2):175-192.
60. Connor CE, Norris JD, Broadwater G, Willson TM, Gottardis MM, Dewhirst MW, McDonnell DP: Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res (2001) 61(7):2917-2922.
61. Smithkline Beecham Corp (Hale RL, Henke BR, Lambert MH, Lu AT, Spearing PK, Turnbull PS): Novel piperazinyltriazines as estrogen receptor modulators. WO-02072561 (2002).